MediWound DSMB sees no safety issues, backs EscharEx Phase III venous leg ulcer trial continuing unchanged

• MediWound reported an independent DSMB review found no safety concerns in its Phase III VALUE trial of EscharEx for venous leg ulcers.
• No efficacy results were presented; the DSMB recommended the study continue without modification.
• Interim sample-size reassessment remains scheduled; patient enrollment completion is still expected by end of Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140700PRIMZONEFULLFEED9825781) on September 14, 2026, and is solely responsible for the information contained therein.